Clinical trial: Renzapride treatment of women with irritable bowel syndrome and constipation - A double-blind, randomized, placebo-controlled, study

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 9, 2010, Pages 979-990

  Lembo, A J ^a   Cremonini, F ^a   Meyers, N ^b   Hickling, R ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Alizyme plc   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RENZAPRIDE; BENZAMIDE DERIVATIVE; FUSED HETEROCYCLIC RINGS; GASTROINTESTINAL AGENT; SEROTONIN ANTAGONIST;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOATING; CLINICAL CHEMISTRY; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION HABIT; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGICAL PARAMETERS; HUMAN; INFECTION; INFESTATION; IRRITABLE COLON; ISCHEMIC COLITIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINUSITIS; TREATMENT OUTCOME; URINALYSIS; URINARY TRACT INFECTION; VITAL SIGN; VOMITING; ADOLESCENT; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BENZAMIDES; BICYCLO COMPOUNDS, HETEROCYCLIC; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; QUALITY OF LIFE; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950574547     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04265.x     Document Type: Article

References (27)

1. Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005 21 : 1365 1375. (Pubitemid 40813683)
2. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000 119 : 654 660.
3. Camilleri M, Williams DE. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics 2000 17 : 331 338. (Pubitemid 30236168)
4. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002 123 : 2108 2131. (Pubitemid 35408332)
5. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009 104 (Suppl. 1 S1 35.
6. Longstreth GFTW, Chey WD, Houghton LA, Mearin F, Spiller RC. Rome III: The Functional Bowel Disorders. Degnon Associates, Inc., VA, 2006.
7. Brandt L, Chey W, Foxx-Orenstein A, et al. American College of Gastroenterology Task Force on Irritable Bowel Syndrome. Am J Gastroenterol 2009 104 : S1 26.
8. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009 29 : 329 341.
9. Thompson CA. Novartis suspends tegaserod sales at FDA's request. Am J Health Syst Pharm 2007 64 : 1020.
10. Ford AC, Brandt LJ, Young C, Chey WD, Foxx-Orenstein AE, Moayyedi P. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009 104 : 1831 1843.
11. Schiller LR, Johnson DA. Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care. Am J Gastroenterol 2008 103 : 815 819.
12. Scarpellini E, Tack J. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin Investig Drugs 2008 17 : 1663 1670.
13. Craig DA, Clarke DE. Peristalsis evoked by 5-HT and renzapride: evidence for putative 5-HT4 receptor activation. Br J Pharmacol 1991 102 : 563 564.
14. Camilleri M, McKinzie S, Fox J, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004 2 : 895 904. (Pubitemid 39335796)
15. George AM, Meyers NL, Hickling RI. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome - multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting. Aliment Pharmacol Ther 2008 27 : 830 837.
16. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999 45 (Suppl. 2 II43 7.
17. Mangel AW, Hahn BA, Heath AT, et al. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome. J Int Med Res 1998 26 : 76 81. (Pubitemid 28211930)
18. Camilleri M. Editorial: is adequate relief fatally flawed or adequate as an end point in irritable bowel syndrome? Am J Gastroenterol 2009 104 : 920 922.
19. Heaton KW, O'Donnell LJ. An office guide to whole-gut transit time. Patients' recollection of their stool form. J Clin Gastroenterol 1994 19 : 28 30.
20. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998 43 : 400 411. (Pubitemid 28124621)
21. Koch GG, Tangen CM, Jung JW, Amara IA. Issues for covariance analysis of dichotomous and ordered categorical data from randomized clinical trials and non-parametric strategies for addressing them. Stat Med 1998 17 : 1863 1892.
22. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990 9 : 811 818. (Pubitemid 20343989)
23. Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 2007 19 (Suppl. 2 25 31. (Pubitemid 47037963)
24. Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006 101 : 1069 1079. (Pubitemid 43725322)
25. Chey WD, Cash BD. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. Expert Opin Investig Drugs 2005 14 : 185 193. (Pubitemid 40403392)
26. Spiegel B, Bolus R, Harris LA, et al. Measuring IBS patient reported outcomes with an abdominal pain numeric rating scale: results from the proof cohort. Aliment Pharmacol Ther 2009 30 (11-12 1159 1170.
27. Patel SM, Stason WB, Legedza A, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005 17 : 332 340. (Pubitemid 40768905)